Literature DB >> 3771576

Glycosphingolipid patterns of the gastrointestinal tract and feces of germ-free and conventional rats.

B E Gustafsson, K A Karlsson, G Larson, T Midtvedt, N Strömberg, S Teneberg, J Thurin.   

Abstract

Acid and non-acid glycosphingolipids of stomach, small and large intestine, and stimulated feces of germ-free and conventional rats of the same stain have been isolated and characterized. The glycosphingolipid patterns of the intestinal organs were chemically and immunologically very similar between the two groups of rats and relatively unaffected by the presence of an intestinal microbial flora. The major exception was the presence of hematoside with N-glycoloylneuraminic acid (NeuGc) (NeuGc alpha 2----3Gal beta 1----4Glc beta 1----1Cer) in the stomach of conventional rats not found in the stomach of germ-free animals. Glycosphingolipids of stimulated feces of germ-free animals were derived from epithelial cells mainly of the small intestine and showed no signs of degradation. Glycosphingolipids of feces of conventional rats completely retained the pattern of blood group A-, B-, and H-active glycolipids as found in sterile feces but contained less of hematoside and more of lactosylceramide. This effect was probably due to degradation by bacteria, as demonstrated in vitro with the production of lactosylceramide after treatment of the isolated acid glycolipids of sterile feces with neuraminidase from Clostridium perfringens. The amount of total non-acid glycosphingolipids per dry weight was similar for stomach, was 50% higher for small intestine, and 300% higher for large intestine of germ-free animals compared to conventional animals. Due to the presence of large amounts of mucins the dry sterile feces contained 12% less non-acid glycolipids than conventional feces. However, calculated per rat per day the germ-free animal excreted more of non-acid glycosphingolipids (1.8 and 1.2 mg, respectively).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3771576

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Excretion into feces of asialo GM1 in the murine digestive tract and Lactobacillus johnsonii exhibiting binding ability toward asialo GM1. A possible role of epithelial glycolipids in the discharge of intestinal bacteria.

Authors:  Masao Iwamori; Yuriko Iwamori; Shigeki Adachi; Taisei Nomura
Journal:  Glycoconj J       Date:  2010-12-21       Impact factor: 2.916

2.  Intestinal sphingolipid excretion associated with feeding of phytohemagglutinin lectin (Phaseolus vulgaris) to germ-free and conventional rats.

Authors:  G Larson; P Falk; R Howard; J G Banwell
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

3.  Glycosphingolipids in feces of germ-free rats as a source for studies of developmental changes of intestinal epithelial cell surface carbohydrates.

Authors:  G Larson; T Midtvedt
Journal:  Glycoconj J       Date:  1989       Impact factor: 2.916

4.  Cardiolipins Act as a Selective Barrier to Toll-Like Receptor 4 Activation in the Intestine.

Authors:  Stephen R Coats; Ahmed Hashim; Nikolay A Paramonov; Thao T To; Michael A Curtis; Richard P Darveau
Journal:  Appl Environ Microbiol       Date:  2016-06-30       Impact factor: 4.792

Review 5.  Consumption of human milk glycoconjugates by infant-associated bifidobacteria: mechanisms and implications.

Authors:  Daniel Garrido; David C Dallas; David A Mills
Journal:  Microbiology       Date:  2013-03-04       Impact factor: 2.777

Review 6.  Immunological function of sphingosine 1-phosphate in the intestine.

Authors:  Jun Kunisawa; Hiroshi Kiyono
Journal:  Nutrients       Date:  2012-03-06       Impact factor: 5.717

Review 7.  Sphingolipids and Epoxidized Lipid Metabolites in the Control of Gut Immunosurveillance and Allergy.

Authors:  Jun Kunisawa; Hiroshi Kiyono
Journal:  Front Nutr       Date:  2016-01-27

8.  Structural differences between the putative carbohydrate-recognition domains of human IL-1 alpha, IL-1 beta and IL-1 receptor antagonist obtained by in silico modeling.

Authors:  Gérard Vergoten; Jean-Pierre Zanetta
Journal:  Glycoconj J       Date:  2007-03-06       Impact factor: 3.009

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.